APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antidiabetic Thiazolidinediones

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Antidiabetic Thiazolidinediones Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025197 pages

Choose your research edition.

Industry ResearchAntidiabetic Thiazolidinediones Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Antidiabetic Thiazolidinediones Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Antidiabetic Thiazolidinediones Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antidiabetic Thiazolidinediones Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Antidiabetic Thiazolidinediones Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Antidiabetic Thiazolidinediones market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Antidiabetic Thiazolidinediones is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antidiabetic Thiazolidinediones is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antidiabetic Thiazolidinediones is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Antidiabetic Thiazolidinediones is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Antidiabetic Thiazolidinediones include Takeda Pharmaceuticals, Sanofi, Merck & Co., Eli Lilly, Pfizer, GlaxoSmithKline, AstraZeneca, Novo Nordisk and Bristol-Myers Squibb, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Antidiabetic Thiazolidinediones market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antidiabetic Thiazolidinediones and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antidiabetic Thiazolidinediones sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Antidiabetic Thiazolidinediones market size, projected growth trends, production technologies, key applications, and end-use industries.

Antidiabetic Thiazolidinediones Segment by Company

Takeda Pharmaceuticals

Sanofi

Merck & Co.

Eli Lilly

Pfizer

GlaxoSmithKline

AstraZeneca

Novo Nordisk

Bristol-Myers Squibb

Boehringer Ingelheim

Antidiabetic Thiazolidinediones Segment by Type

Rosiglitazone

Pioglitazone

Antidiabetic Thiazolidinediones Segment by Application

Hospitals

Clinics

Other

Antidiabetic Thiazolidinediones Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antidiabetic Thiazolidinediones market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antidiabetic Thiazolidinediones and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antidiabetic Thiazolidinediones.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Antidiabetic Thiazolidinediones market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Antidiabetic Thiazolidinediones manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Antidiabetic Thiazolidinediones in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Antidiabetic Thiazolidinediones in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Antidiabetic Thiazolidinediones Industry Trends Table 2. Antidiabetic Thiazolidinediones Industry Drivers Table 3. Antidiabetic Thiazolidinediones Industry Opportunities and Challenges Table 4. Antidiabetic Thiazolidinediones Industry Restraints Table 5. Global Antidiabetic Thiazolidinediones Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Antidiabetic Thiazolidinediones Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Antidiabetic Thiazolidinediones Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Antidiabetic Thiazolidinediones Sales Market Share by Manufacturers Table 9. Global Antidiabetic Thiazolidinediones Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Antidiabetic Thiazolidinediones Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Antidiabetic Thiazolidinediones Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Antidiabetic Thiazolidinediones Manufacturers, Product Type & Application Table 13. Global Antidiabetic Thiazolidinediones Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Antidiabetic Thiazolidinediones by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Rosiglitazone Table 17. Major Manufacturers of Pioglitazone Table 18. Global Antidiabetic Thiazolidinediones Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Antidiabetic Thiazolidinediones Sales by Type (2021-2026) & (K Units) Table 20. Global Antidiabetic Thiazolidinediones Sales by Type (2027-2032) & (K Units) Table 21. Global Antidiabetic Thiazolidinediones Sales Market Share by Type (2021-2026) Table 22. Global Antidiabetic Thiazolidinediones Sales Market Share by Type (2027-2032) Table 23. Global Antidiabetic Thiazolidinediones Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Antidiabetic Thiazolidinediones Revenue by Type (2021-2026) & (K Units) Table 25. Global Antidiabetic Thiazolidinediones Revenue by Type (2027-2032) & (K Units) Table 26. Global Antidiabetic Thiazolidinediones Revenue Market Share by Type (2021-2026) Table 27. Global Antidiabetic Thiazolidinediones Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospitals Table 29. Major Manufacturers of Clinics Table 30. Major Manufacturers of Other Table 31. Global Antidiabetic Thiazolidinediones Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Antidiabetic Thiazolidinediones Sales by Application (2021-2026) & (K Units) Table 33. Global Antidiabetic Thiazolidinediones Sales by Application (2027-2032) & (K Units) Table 34. Global Antidiabetic Thiazolidinediones Sales Market Share by Application (2021-2026) Table 35. Global Antidiabetic Thiazolidinediones Sales Market Share by Application (2027-2032) Table 36. Global Antidiabetic Thiazolidinediones Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Antidiabetic Thiazolidinediones Revenue by Application (2021-2026) & (K Units) Table 38. Global Antidiabetic Thiazolidinediones Revenue by Application (2027-2032) & (K Units) Table 39. Global Antidiabetic Thiazolidinediones Revenue Market Share by Application (2021-2026) Table 40. Global Antidiabetic Thiazolidinediones Revenue Market Share by Application (2027-2032) Table 41. Global Antidiabetic Thiazolidinediones Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Antidiabetic Thiazolidinediones Sales by Region (2021-2026) & (K Units) Table 43. Global Antidiabetic Thiazolidinediones Sales Market Share by Region (2021-2026) Table 44. Global Antidiabetic Thiazolidinediones Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Antidiabetic Thiazolidinediones Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Antidiabetic Thiazolidinediones Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Antidiabetic Thiazolidinediones Sales by Country (2021-2026) & (K Units) Table 48. North America Antidiabetic Thiazolidinediones Sales by Country (2027-2032) & (K Units) Table 49. Europe Antidiabetic Thiazolidinediones Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Antidiabetic Thiazolidinediones Sales by Country (2021-2026) & (K Units) Table 51. Europe Antidiabetic Thiazolidinediones Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Antidiabetic Thiazolidinediones Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Antidiabetic Thiazolidinediones Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Antidiabetic Thiazolidinediones Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Antidiabetic Thiazolidinediones Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Antidiabetic Thiazolidinediones Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Antidiabetic Thiazolidinediones Sales by Country (2027-2032) & (K Units) Table 58. Global Antidiabetic Thiazolidinediones Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Antidiabetic Thiazolidinediones Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Antidiabetic Thiazolidinediones Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Antidiabetic Thiazolidinediones Revenue Market Share by Region (2021-2026) Table 62. Global Antidiabetic Thiazolidinediones Revenue Market Share by Region (2027-2032) Table 63. Takeda Pharmaceuticals Company Information Table 64. Takeda Pharmaceuticals Business Overview Table 65. Takeda Pharmaceuticals Antidiabetic Thiazolidinediones Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Takeda Pharmaceuticals Antidiabetic Thiazolidinediones Product Portfolio Table 67. Takeda Pharmaceuticals Recent Development Table 68. Sanofi Company Information Table 69. Sanofi Business Overview Table 70. Sanofi Antidiabetic Thiazolidinediones Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Sanofi Antidiabetic Thiazolidinediones Product Portfolio Table 72. Sanofi Recent Development Table 73. Merck & Co. Company Information Table 74. Merck & Co. Business Overview Table 75. Merck & Co. Antidiabetic Thiazolidinediones Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Merck & Co. Antidiabetic Thiazolidinediones Product Portfolio Table 77. Merck & Co. Recent Development Table 78. Eli Lilly Company Information Table 79. Eli Lilly Business Overview Table 80. Eli Lilly Antidiabetic Thiazolidinediones Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Eli Lilly Antidiabetic Thiazolidinediones Product Portfolio Table 82. Eli Lilly Recent Development Table 83. Pfizer Company Information Table 84. Pfizer Business Overview Table 85. Pfizer Antidiabetic Thiazolidinediones Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Pfizer Antidiabetic Thiazolidinediones Product Portfolio Table 87. Pfizer Recent Development Table 88. GlaxoSmithKline Company Information Table 89. GlaxoSmithKline Business Overview Table 90. GlaxoSmithKline Antidiabetic Thiazolidinediones Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. GlaxoSmithKline Antidiabetic Thiazolidinediones Product Portfolio Table 92. GlaxoSmithKline Recent Development Table 93. AstraZeneca Company Information Table 94. AstraZeneca Business Overview Table 95. AstraZeneca Antidiabetic Thiazolidinediones Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. AstraZeneca Antidiabetic Thiazolidinediones Product Portfolio Table 97. AstraZeneca Recent Development Table 98. Novo Nordisk Company Information Table 99. Novo Nordisk Business Overview Table 100. Novo Nordisk Antidiabetic Thiazolidinediones Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Novo Nordisk Antidiabetic Thiazolidinediones Product Portfolio Table 102. Novo Nordisk Recent Development Table 103. Bristol-Myers Squibb Company Information Table 104. Bristol-Myers Squibb Business Overview Table 105. Bristol-Myers Squibb Antidiabetic Thiazolidinediones Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Bristol-Myers Squibb Antidiabetic Thiazolidinediones Product Portfolio Table 107. Bristol-Myers Squibb Recent Development Table 108. Boehringer Ingelheim Company Information Table 109. Boehringer Ingelheim Business Overview Table 110. Boehringer Ingelheim Antidiabetic Thiazolidinediones Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Boehringer Ingelheim Antidiabetic Thiazolidinediones Product Portfolio Table 112. Boehringer Ingelheim Recent Development Table 113. Key Raw Materials Table 114. Raw Materials Key Suppliers Table 115. Antidiabetic Thiazolidinediones Distributors List Table 116. Antidiabetic Thiazolidinediones Customers List Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. Antidiabetic Thiazolidinediones Product Image Figure 2. Global Antidiabetic Thiazolidinediones Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antidiabetic Thiazolidinediones Market Size (2021-2032) & (US$ Million) Figure 4. Global Antidiabetic Thiazolidinediones Sales (2021-2032) & (K Units) Figure 5. Global Antidiabetic Thiazolidinediones Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Antidiabetic Thiazolidinediones Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Rosiglitazone Image Figure 9. Pioglitazone Image Figure 10. Global Antidiabetic Thiazolidinediones Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Antidiabetic Thiazolidinediones Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Antidiabetic Thiazolidinediones Sales Market Share by Type (2021-2032) Figure 13. Global Antidiabetic Thiazolidinediones Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Antidiabetic Thiazolidinediones Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Antidiabetic Thiazolidinediones Revenue Market Share by Type (2021-2032) Figure 16. Hospitals Image Figure 17. Clinics Image Figure 18. Other Image Figure 19. Global Antidiabetic Thiazolidinediones Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Antidiabetic Thiazolidinediones Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Antidiabetic Thiazolidinediones Sales Market Share by Application (2021-2032) Figure 22. Global Antidiabetic Thiazolidinediones Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Antidiabetic Thiazolidinediones Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Antidiabetic Thiazolidinediones Revenue Market Share by Application (2021-2032) Figure 25. North America Antidiabetic Thiazolidinediones Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Antidiabetic Thiazolidinediones Sales Market Share by Country (2021-2032) Figure 27. U.S. Antidiabetic Thiazolidinediones Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Antidiabetic Thiazolidinediones Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Antidiabetic Thiazolidinediones Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Antidiabetic Thiazolidinediones Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Antidiabetic Thiazolidinediones Sales Market Share by Country (2021-2032) Figure 32. Germany Antidiabetic Thiazolidinediones Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Antidiabetic Thiazolidinediones Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Antidiabetic Thiazolidinediones Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Antidiabetic Thiazolidinediones Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Antidiabetic Thiazolidinediones Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Antidiabetic Thiazolidinediones Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Antidiabetic Thiazolidinediones Sales Market Share by Country (2021-2032) Figure 39. China Antidiabetic Thiazolidinediones Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Antidiabetic Thiazolidinediones Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Antidiabetic Thiazolidinediones Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Antidiabetic Thiazolidinediones Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Antidiabetic Thiazolidinediones Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Antidiabetic Thiazolidinediones Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Antidiabetic Thiazolidinediones Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Antidiabetic Thiazolidinediones Sales Market Share by Country (2021-2032) Figure 47. Brazil Antidiabetic Thiazolidinediones Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Antidiabetic Thiazolidinediones Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Antidiabetic Thiazolidinediones Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Antidiabetic Thiazolidinediones Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Antidiabetic Thiazolidinediones Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Antidiabetic Thiazolidinediones Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Antidiabetic Thiazolidinediones Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Antidiabetic Thiazolidinediones Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Antidiabetic Thiazolidinediones Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Antidiabetic Thiazolidinediones Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Antidiabetic Thiazolidinediones Revenue (2021-2032) & (US$ Million) Figure 58. North America Antidiabetic Thiazolidinediones Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Antidiabetic Thiazolidinediones Revenue (2021-2032) & (US$ Million) Figure 60. Europe Antidiabetic Thiazolidinediones Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Antidiabetic Thiazolidinediones Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Antidiabetic Thiazolidinediones Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Antidiabetic Thiazolidinediones Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Antidiabetic Thiazolidinediones Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Antidiabetic Thiazolidinediones Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Antidiabetic Thiazolidinediones Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Rosiglitazone
  • Pioglitazone
Applications
  • Hospitals
  • Clinics
  • Other
Companies covered
  • Takeda Pharmaceuticals
  • Sanofi
  • Merck & Co.
  • Eli Lilly
  • Pfizer
  • GlaxoSmithKline
  • AstraZeneca
  • Novo Nordisk
  • Bristol-Myers Squibb
  • Boehringer Ingelheim

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Antidiabetic Thiazolidinediones Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Antidiabetic Thiazolidinediones Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Antidiabetic Thiazolidinediones Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Antidiabetic Thiazolidinediones Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Antidiabetic Thiazolidinediones Market Dynamics
  1. 2.1 Antidiabetic Thiazolidinediones Industry Trends
  2. 2.2 Antidiabetic Thiazolidinediones Industry Drivers
  3. 2.3 Antidiabetic Thiazolidinediones Industry Opportunities and Challenges
  4. 2.4 Antidiabetic Thiazolidinediones Industry Restraints
3 Antidiabetic Thiazolidinediones Market by Manufacturers
  1. 3.1 Global Antidiabetic Thiazolidinediones Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Antidiabetic Thiazolidinediones Sales by Manufacturers (2021-2026)
  3. 3.3 Global Antidiabetic Thiazolidinediones Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Antidiabetic Thiazolidinediones Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Antidiabetic Thiazolidinediones Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Antidiabetic Thiazolidinediones Manufacturers, Product Type & Application
  7. 3.7 Global Antidiabetic Thiazolidinediones Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Antidiabetic Thiazolidinediones Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Antidiabetic Thiazolidinediones Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Antidiabetic Thiazolidinediones Tier 1, Tier 2, and Tier 3
4 Antidiabetic Thiazolidinediones Market by Type
  1. 4.1 Antidiabetic Thiazolidinediones Type Introduction
  2. 4.1.1 Rosiglitazone
  3. 4.1.2 Pioglitazone
  4. 4.2 Global Antidiabetic Thiazolidinediones Sales by Type
  5. 4.2.1 Global Antidiabetic Thiazolidinediones Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Antidiabetic Thiazolidinediones Sales by Type (2021-2032)
  7. 4.2.3 Global Antidiabetic Thiazolidinediones Sales Market Share by Type (2021-2032)
  8. 4.3 Global Antidiabetic Thiazolidinediones Revenue by Type
  9. 4.3.1 Global Antidiabetic Thiazolidinediones Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Antidiabetic Thiazolidinediones Revenue by Type (2021-2032)
  11. 4.3.3 Global Antidiabetic Thiazolidinediones Revenue Market Share by Type (2021-2032)
5 Antidiabetic Thiazolidinediones Market by Application
  1. 5.1 Antidiabetic Thiazolidinediones Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Other
  5. 5.2 Global Antidiabetic Thiazolidinediones Sales by Application
  6. 5.2.1 Global Antidiabetic Thiazolidinediones Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Antidiabetic Thiazolidinediones Sales by Application (2021-2032)
  8. 5.2.3 Global Antidiabetic Thiazolidinediones Sales Market Share by Application (2021-2032)
  9. 5.3 Global Antidiabetic Thiazolidinediones Revenue by Application
  10. 5.3.1 Global Antidiabetic Thiazolidinediones Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Antidiabetic Thiazolidinediones Revenue by Application (2021-2032)
  12. 5.3.3 Global Antidiabetic Thiazolidinediones Revenue Market Share by Application (2021-2032)
6 Global Antidiabetic Thiazolidinediones Sales by Region
  1. 6.1 Global Antidiabetic Thiazolidinediones Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antidiabetic Thiazolidinediones Sales by Region (2021-2032)
  3. 6.2.1 Global Antidiabetic Thiazolidinediones Sales by Region (2021-2026)
  4. 6.2.2 Global Antidiabetic Thiazolidinediones Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Antidiabetic Thiazolidinediones Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Antidiabetic Thiazolidinediones Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Antidiabetic Thiazolidinediones Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Antidiabetic Thiazolidinediones Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Antidiabetic Thiazolidinediones Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Antidiabetic Thiazolidinediones Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Antidiabetic Thiazolidinediones Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Antidiabetic Thiazolidinediones Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Antidiabetic Thiazolidinediones Revenue by Region
  1. 7.1 Global Antidiabetic Thiazolidinediones Revenue by Region
  2. 7.1.1 Global Antidiabetic Thiazolidinediones Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Antidiabetic Thiazolidinediones Revenue by Region (2021-2026)
  4. 7.1.3 Global Antidiabetic Thiazolidinediones Revenue by Region (2027-2032)
  5. 7.1.4 Global Antidiabetic Thiazolidinediones Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Antidiabetic Thiazolidinediones Revenue (2021-2032)
  8. 7.2.2 North America Antidiabetic Thiazolidinediones Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Antidiabetic Thiazolidinediones Revenue (2021-2032)
  11. 7.3.2 Europe Antidiabetic Thiazolidinediones Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Antidiabetic Thiazolidinediones Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Antidiabetic Thiazolidinediones Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Antidiabetic Thiazolidinediones Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Antidiabetic Thiazolidinediones Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceuticals
  2. 8.1.1 Takeda Pharmaceuticals Company Information
  3. 8.1.2 Takeda Pharmaceuticals Business Overview
  4. 8.1.3 Takeda Pharmaceuticals Antidiabetic Thiazolidinediones Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceuticals Antidiabetic Thiazolidinediones Product Portfolio
  6. 8.1.5 Takeda Pharmaceuticals Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Antidiabetic Thiazolidinediones Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Antidiabetic Thiazolidinediones Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Merck & Co.
  14. 8.3.1 Merck & Co. Company Information
  15. 8.3.2 Merck & Co. Business Overview
  16. 8.3.3 Merck & Co. Antidiabetic Thiazolidinediones Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck & Co. Antidiabetic Thiazolidinediones Product Portfolio
  18. 8.3.5 Merck & Co. Recent Developments
  19. 8.4 Eli Lilly
  20. 8.4.1 Eli Lilly Company Information
  21. 8.4.2 Eli Lilly Business Overview
  22. 8.4.3 Eli Lilly Antidiabetic Thiazolidinediones Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Eli Lilly Antidiabetic Thiazolidinediones Product Portfolio
  24. 8.4.5 Eli Lilly Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Antidiabetic Thiazolidinediones Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Antidiabetic Thiazolidinediones Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 GlaxoSmithKline
  32. 8.6.1 GlaxoSmithKline Company Information
  33. 8.6.2 GlaxoSmithKline Business Overview
  34. 8.6.3 GlaxoSmithKline Antidiabetic Thiazolidinediones Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 GlaxoSmithKline Antidiabetic Thiazolidinediones Product Portfolio
  36. 8.6.5 GlaxoSmithKline Recent Developments
  37. 8.7 AstraZeneca
  38. 8.7.1 AstraZeneca Company Information
  39. 8.7.2 AstraZeneca Business Overview
  40. 8.7.3 AstraZeneca Antidiabetic Thiazolidinediones Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 AstraZeneca Antidiabetic Thiazolidinediones Product Portfolio
  42. 8.7.5 AstraZeneca Recent Developments
  43. 8.8 Novo Nordisk
  44. 8.8.1 Novo Nordisk Company Information
  45. 8.8.2 Novo Nordisk Business Overview
  46. 8.8.3 Novo Nordisk Antidiabetic Thiazolidinediones Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Novo Nordisk Antidiabetic Thiazolidinediones Product Portfolio
  48. 8.8.5 Novo Nordisk Recent Developments
  49. 8.9 Bristol-Myers Squibb
  50. 8.9.1 Bristol-Myers Squibb Company Information
  51. 8.9.2 Bristol-Myers Squibb Business Overview
  52. 8.9.3 Bristol-Myers Squibb Antidiabetic Thiazolidinediones Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Bristol-Myers Squibb Antidiabetic Thiazolidinediones Product Portfolio
  54. 8.9.5 Bristol-Myers Squibb Recent Developments
  55. 8.10 Boehringer Ingelheim
  56. 8.10.1 Boehringer Ingelheim Company Information
  57. 8.10.2 Boehringer Ingelheim Business Overview
  58. 8.10.3 Boehringer Ingelheim Antidiabetic Thiazolidinediones Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Boehringer Ingelheim Antidiabetic Thiazolidinediones Product Portfolio
  60. 8.10.5 Boehringer Ingelheim Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Antidiabetic Thiazolidinediones Value Chain Analysis
  2. 9.1.1 Antidiabetic Thiazolidinediones Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Antidiabetic Thiazolidinediones Production Mode & Process
  6. 9.2 Antidiabetic Thiazolidinediones Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Antidiabetic Thiazolidinediones Distributors
  9. 9.2.3 Antidiabetic Thiazolidinediones Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst